Baudax Bio: Funding, Investors & Team (Oct 2026)
Baudax Bio is a specialty pharmaceutical company that generates revenue by developing and selling innovative products for acute care settings. They have multiple non-opioid therapies in development for treating pain conditions and are currently promoting their main product, ANJESO™, which is used for managing moderate-to-severe pain in adults. The company also has other early-stage products, including two new neuromuscular blocker agents and a chemical reversal agent, as well as Dex-IN, an intranasal formulation of dexmedetomidine, a drug with sedative, analgesic, and anxiolytic properties. Baudax Bio believes that its strong pipeline of products can benefit both patients and shareholders. Furthermore, they are actively exploring acquisition and licensing opportunities that align with their focus on acute care.
Baudax Bio has raised $1.9M across 1 funding round on record, the most recent an undisclosed round of $1.9M announced in Aug 2023.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Baudax Bio Company Profile and Key Stats
Latest funding round on record: Aug 2023.
Baudax Bio Funding Rounds
Baudax Bio Founders and Leadership Team
Contact details for the Baudax Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →Baudax Bio Funding Compared to Other Biotechnology Startups
Baudax Bio's latest round of $1.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Baudax Bio in Biotechnology and Malvern
Companies Similar to Baudax Bio
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Baudax Bio Funding FAQs
What does Baudax Bio do?
Baudax Bio is a specialty pharmaceutical company that generates revenue by developing and selling innovative products for acute care settings. They have multiple non-opioid therapies in development for treating pain conditions and are currently promoting their main product, ANJESO™, which is used for managing moderate-to-severe pain in adults. The company also has other early-stage products, including two new neuromuscular blocker agents and a chemical reversal agent, as well as Dex-IN, an intranasal formulation of dexmedetomidine, a drug with sedative, analgesic, and anxiolytic properties. Baudax Bio believes that its strong pipeline of products can benefit both patients and shareholders. Furthermore, they are actively exploring acquisition and licensing opportunities that align with their focus on acute care.
How much funding has Baudax Bio raised?
Baudax Bio has raised $1.9M across 1 round on record. The most recent is an undisclosed round of $1.9M announced in Aug 2023.
When did Baudax Bio last raise funding?
Baudax Bio's most recent funding round on record is an undisclosed round of $1.9M, announced in Aug 2023.
Who founded Baudax Bio?
FundedIQ lists Janice Trulli (Founder) at Baudax Bio.
Where is Baudax Bio headquartered?
Baudax Bio is based in Malvern, Pennsylvania, United States.
How many employees does Baudax Bio have?
Baudax Bio is in the 51-100 employee band.
How does Baudax Bio's funding compare to other Biotechnology startups?
Baudax Bio's latest round of $1.9M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Baudax Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Baudax Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.